Literature DB >> 20376536

Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo.

Yin-He Wang1, Jin Xiong, Shou-Feng Wang, Yang Yu, Bin Wang, Yi-Xin Chen, Hong-Fei Shi, Yong Qiu.   

Abstract

The overexpression of the type 1 insulin-like growth factor receptor (IGF-1R) has been reported to be associated with malignant transformation, tumor development and chemo- or radioresistance of tumor cells. Previously, we have reported that inhibition of IGF-1R could reverse the radioresistance of human osteosarcoma cells. However, whether inhibition of IGF-1R could enhance chemosensitivity of ostesosarcoma cells is unclear. In this study, lentivirus-mediated shRNA was employed to downregulate endogenous IGF-1R expression to study the function of IGF-1R in chemoresistance of osteosarcoma cells. Results showed that lentivirus-mediated shRNA targeting IGF-1R combined with chemotherapy (CDDP or DTX) could lead to growth suppression of osteosarcoma cells not only in vitro but also in vivo. Moreover, inhibition of IGF-1R gene combined with chemotherapy also synergistically enhanced Caspase-3-mediated apoptosis of osteosarcoma cells. The synergistical enhancement of apoptosis might be associated with downregulation of Bcl-2 and upregulation of Bax in osteosarcoma cells induced by IGF-1R inhibition. Therefore, the overexpression of IGF-1R gene might play important roles in chemoresistance of osteosarcoma cells, and lentivirus-mediated RNAi targeting IGF-1R would be an attractive anti-cancer strategy to chemosensitization of osteosarcoma cell.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20376536     DOI: 10.1007/s11010-010-0453-2

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  22 in total

Review 1.  siRNAs: mechanism of RNA interference, in vivo and potential clinical applications.

Authors:  Tom C Karagiannis; Assam El-Osta
Journal:  Cancer Biol Ther       Date:  2004-11-12       Impact factor: 4.742

Review 2.  The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors.

Authors:  A Grothey; W Voigt; C Schöber; T Müller; W Dempke; H J Schmoll
Journal:  J Cancer Res Clin Oncol       Date:  1999       Impact factor: 4.553

Review 3.  The insulin-like growth factor system and sarcomas.

Authors:  Bart Rikhof; Steven de Jong; Albert J H Suurmeijer; Coby Meijer; Winette T A van der Graaf
Journal:  J Pathol       Date:  2009-03       Impact factor: 7.996

4.  Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells.

Authors:  Katia Scotlandi; Sofia Avnet; Stefania Benini; Maria Cristina Manara; Massimo Serra; Vanessa Cerisano; Stefania Perdichizzi; Pier-Luigi Lollini; Carla De Giovanni; Lorena Landuzzi; Piero Picci
Journal:  Int J Cancer       Date:  2002-09-01       Impact factor: 7.396

5.  Lentivirus vector can be readministered to nasal epithelia without blocking immune responses.

Authors:  Patrick L Sinn; Ariadna C Arias; Kim A Brogden; Paul B McCray
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

6.  Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells.

Authors:  Yin-He Wang; Zhao-Xia Wang; Yong Qiu; Jin Xiong; Yi-Xin Chen; Deng-Shun Miao; Wei De
Journal:  Mol Cell Biochem       Date:  2009-02-20       Impact factor: 3.396

Review 7.  Osteosarcoma.

Authors:  Patrick J Messerschmitt; Ryan M Garcia; Fadi W Abdul-Karim; Edward M Greenfield; Patrick J Getty
Journal:  J Am Acad Orthop Surg       Date:  2009-08       Impact factor: 3.020

Review 8.  The insulin-like growth factor-I receptor as an oncogene.

Authors:  Haim Werner; Ilan Bruchim
Journal:  Arch Physiol Biochem       Date:  2009-05       Impact factor: 4.076

Review 9.  Development of IGF-IR Inhibitors in Pediatric Sarcomas.

Authors:  E Anders Kolb; Richard Gorlick
Journal:  Curr Oncol Rep       Date:  2009-07       Impact factor: 5.075

Review 10.  Insulin resistance and hyperinsulinaemia in the development and progression of cancer.

Authors:  Ian F Godsland
Journal:  Clin Sci (Lond)       Date:  2009-11-23       Impact factor: 6.124

View more
  12 in total

1.  Down-regulation of IGF-1R expression inhibits growth and enhances chemosensitivity of endometrial carcinoma in vitro.

Authors:  Shanrong Shu; Yuebo Yang; Xiaomao Li; Tian Li; Yu Zhang; Chengfang Xu; Changyan Liang; Xiaoyun Wang
Journal:  Mol Cell Biochem       Date:  2011-03-26       Impact factor: 3.396

Review 2.  Targeting the insulin growth factor receptor 1.

Authors:  Fernanda I Arnaldez; Lee J Helman
Journal:  Hematol Oncol Clin North Am       Date:  2012-02-28       Impact factor: 3.722

Review 3.  Targeting protein kinases to reverse multidrug resistance in sarcoma.

Authors:  Hua Chen; Jacson Shen; Edwin Choy; Francis J Hornicek; Zhenfeng Duan
Journal:  Cancer Treat Rev       Date:  2015-12-08       Impact factor: 12.111

4.  The molecular pathogenesis of osteosarcoma: a review.

Authors:  Matthew L Broadhead; Jonathan C M Clark; Damian E Myers; Crispin R Dass; Peter F M Choong
Journal:  Sarcoma       Date:  2011-04-13

5.  Molecular alterations associated with osteosarcoma development.

Authors:  Kosei Ando; Kanji Mori; Franck Verrecchia; Baud'huin Marc; Françoise Rédini; Dominique Heymann
Journal:  Sarcoma       Date:  2012-02-15

6.  Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance.

Authors:  Sahitya K Denduluri; Olumuyiwa Idowu; Zhongliang Wang; Zhan Liao; Zhengjian Yan; Maryam K Mohammed; Jixing Ye; Qiang Wei; Jing Wang; Lianggong Zhao; Hue H Luu
Journal:  Genes Dis       Date:  2015-03-01

7.  Molecular mechanisms of chemoresistance in osteosarcoma (Review).

Authors:  Hongtao He; Jiangdong Ni; Jun Huang
Journal:  Oncol Lett       Date:  2014-03-04       Impact factor: 2.967

8.  MiR-133b is down-regulated in human osteosarcoma and inhibits osteosarcoma cells proliferation, migration and invasion, and promotes apoptosis.

Authors:  Huafu Zhao; Mei Li; Lihua Li; Xiaoming Yang; Guobo Lan; Yu Zhang
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

9.  A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.

Authors:  Zhenfeng Duan; Jianming Zhang; Shunan Ye; Jacson Shen; Edwin Choy; Gregory Cote; David Harmon; Henry Mankin; Yingqi Hua; Yu Zhang; Nathanael S Gray; Francis J Hornicek
Journal:  BMC Cancer       Date:  2014-09-19       Impact factor: 4.430

Review 10.  Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression.

Authors:  Limin Zhu; Madonna M McManus; Dennis P M Hughes
Journal:  Front Oncol       Date:  2013-09-17       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.